SER
21.3.2024 17:11:30 CET | Business Wire | Press release
SER (the “Company”), a leading global Intelligent Content Automation (“ICA”) software vendor in the Enterprise Content Management (“ECM”) market, today announced that TA Associates (“TA”), a leading global private equity firm, has agreed to make a strategic growth investment in the Company. SER and Carlyle, an investor in SER since 2018, welcome TA as the new lead investor.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321414321/en/
“We are delighted to welcome TA to SER as an investor and we are proud that they share our perspective on the significant opportunities ahead for our business,” said Dr. John Bates, CEO of SER. “SER is revolutionizing the way enterprise content is automated, understood and managed. We have amazing customers, a fantastic team and market leading technology. We have had an outstanding partnership with Carlyle, with incredible support throughout the journey, and we are delighted that TA now joins us to supercharge the next phase of growth.”
Since its founding in 1984, SER has developed from a primarily DACH-focused ECM solutions provider into a category-defining ICA player with highly differentiated AI capabilities and an increasingly international enterprise customer base. In partnership with Carlyle, SER built out its senior management team, successfully executed a rapid shift to a subscription-first business model, expanded its innovation-led product offering, and entered new markets including the US, UK, continental Europe, and the Middle East, through considerable organic investment and M&A.
Today, SER has over 600 employees across 20 offices in 11 countries. The Company’s technology is trusted by blue-chip enterprise customers worldwide. SER’s flagship product, Doxis ICA (“Doxis”), combines traditional ECM capabilities with AI-enabled services that are designed to bridge and automate content across best-of-breed apps and multiple vendor ecosystems like SAP, Salesforce, Microsoft and more.
“SER’s impressive suite of next-generation ECM solutions helps organizations work faster, smarter and more efficiently,” said Morgan Seigler, Managing Director at TA, and Stefan Dandl, Director at TA. “As the demand for AI-powered technologies continues, we believe SER has a meaningful opportunity to support organizations in their digital transformation journey, harnessing the Doxis platform to streamline document processing and content management needs. We look forward to partnering with Carlyle and SER to accelerate international expansion, invest in AI innovation and enhance the Company’s product offering.”
“We are immensely proud to have partnered with SER during such a significant period of growth and transformation for the business,” said Dr. Thorsten Dippel, Managing Director in the Carlyle Europe Technology Partners (“CETP”) Investment Advisory team. “Through our work with Dr. John Bates and his incredible team, the Company has developed into the category-leading, international ICA software vendor it is today. SER is well-placed to continue its success story as an enterprise software player of scale in the large and growing global ECM market. We are delighted to partner with TA as the new lead investor in SER as the Company enters the next phase of its growth journey.”
The transaction is subject to customary regulatory approvals.
About SER
Trusted by over 5 million users worldwide, SER is defining Intelligent Content Automation (ICA), the next generation of Enterprise Content Management which leverages AI to provide intelligent content understanding and process automation. SER’s highly scalable Doxis platform brings ICA capabilities into a single, unified platform that works seamlessly across multiple applications and vendor ecosystems, such as SAP, Salesforce and Microsoft. Offering many pre-built solutions and user-friendly no-code tooling, SER’s Doxis delivers rapid time-to-value, superior ROI and lower total cost of ownership for next-generation content applications. Headquartered in Bonn, Germany, SER has a well-established market leadership position in DACH and a fast-growing international business with blue-chip customers around the world.
About TA
TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five target industries – technology, healthcare, financial services, consumer and business services. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has over 150 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com.
About Carlyle
Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across its business and conducts its operations through three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With $426 billion of assets under management as of December 31, 2023, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 2,200 people in 28 offices across four continents. Further information is available at www.carlyle.com. For more, follow Carlyle on LinkedIn and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321414321/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
